{"product_id":"phr-vrio-analysis","title":"Phreesia, Inc. (PHR): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Phreesia, Inc. (PHR)'s enduring success starts here: this VRIO analysis distills exactly where its competitive advantage lies, based on the findings in \u0026amp;O4\u0026amp;. Are its core assets truly Valuable, Rare, Inimitable, and Organized for sustained dominance? Click through below to see the sharp, one-paragraph summary and find out if Phreesia, Inc. (PHR) is built to last.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Established Healthcare Services Client Network (\u003cstrong\u003e4,520\u003c\/strong\u003e AHSCs as of Q3 FY2026)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at Phreesia, Inc.'s core asset here: that deeply embedded network of healthcare providers. This isn't just a list of customers; it’s the operational backbone that drives everything else they do. Honestly, this installed base is what makes their growth story compelling, even with the recent acquisition of AccessOne.\u003c\/p\u003e\n\u003cp\u003eThe numbers from the fiscal third quarter ended October 31, 2025, really drive this home. They had 4,520 Average Healthcare Services Clients (AHSCs). That scale means they have a massive, recurring revenue base and a direct channel for upselling new products, like their payment solutions. It’s a powerful flywheel, if you can keep it spinning.\u003c\/p\u003e\n\n\u003ch3 id=\"value\"\u003eValue: Monetizing the Installed Base\u003c\/h3\u003e\n\u003cp\u003eThe value is clear: it’s a massive, recurring revenue stream. More importantly, it’s the direct pipeline for expanding revenue within each client relationship. Think about it - it’s much cheaper to sell a new module to an existing client than to land a brand new one from scratch. This is why Total revenue per AHSC grew by 6% year-over-year in Q3 FY2026, reaching $26,622 for that quarter.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the Q3 FY2026 performance that this network supported:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q3 FY2026)\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp 13%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue per AHSC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26,622\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e6%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from net loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThat 6% growth in revenue per client is the real signal of value extraction. If onboarding takes 14+ days, churn risk rises.\u003c\/p\u003e\n\n\u003ch3 id=\"rarity\"\u003eRarity: Unmatched Scale and Workflow Integration\u003c\/h3\u003e\n\u003cp\u003eIs this rare? I’d say yes, at this specific scale. While there are definitely competitors in the patient engagement space, the sheer depth of integration into the daily workflow of over 4,520 AHSCs is tough to replicate quickly. It’s not just that they have the clients; it’s that they are in the workflow.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is the concentration risk; if a major EHR vendor decides to bundle a competing feature, the impact could be significant. Still, the current footprint is rare.\u003c\/p\u003e\n\n\u003ch3 id=\"imitability\"\u003eImitability: The Cost of Time and Trust\u003c\/h3\u003e\n\u003cp\u003eThis is difficult to copy. It took years of dedicated sales cycles, complex IT integration, and building provider trust to embed Phreesia so deeply into the operational fabric of these practices. You can’t just buy this overnight, even with the AccessOne deal closing for about $160 million. That acquisition adds to the network, but the original core took a long time to build.\u003c\/p\u003e\n\u003cp\u003eKey factors making imitation hard:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLong, sticky sales cycles.\u003c\/li\u003e\n\u003cli\u003eDeep integration into provider systems.\u003c\/li\u003e\n\u003cli\u003eEstablished trust with clinical staff.\u003c\/li\u003e\n\u003cli\u003eHigh switching costs for providers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3 id=\"organization\"\u003eOrganization: Structured for Monetization\u003c\/h3\u003e\n\u003cp\u003eThe organization seems strong enough to capitalize on this asset, which is why we see consistent monetization. They are defintely organized to drive revenue from this base, as evidenced by the consistent YoY growth in revenue per client.\u003c\/p\u003e\n\u003cp\u003eTheir organizational structure supports this network through:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsistent focus on upselling payment solutions.\u003c\/li\u003e\n\u003cli\u003ePositive operating cash flow of $15.5 million in Q3 FY2026.\u003c\/li\u003e\n\u003cli\u003eRaising the FY2026 Adjusted EBITDA outlook to $99 million to $101 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3 id=\"competitive-advantage\"\u003eCompetitive Advantage: Sustained\u003c\/h3\u003e\n\u003cp\u003eBecause the network is valuable, rare, and hard to copy, it creates a sustained competitive advantage. This network effect acts as a high barrier to entry for any new player trying to challenge Phreesia at scale. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Proprietary Patient Activation \u0026amp; Intake Platform Technology\n\u003c\/h2\u003e\n\u003cp\u003eProprietary Patient Activation \u0026amp; Intake Platform Technology\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eDrives efficiency for providers and enhances patient experience, which is key to retaining clients and justifying subscription fees (\u003cstrong\u003e46%\u003c\/strong\u003e of Q3 FY2026 revenue). The platform supports a client base of \u003cstrong\u003e4,520\u003c\/strong\u003e Average Healthcare Services Clients (AHSCs) as of Q3 FY2026.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Q3 FY2026)\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription \u0026amp; Related Services Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork Solutions Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayment Processing Fees Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue per AHSC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26,622\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Many firms have patient portals, but Phreesia’s integrated, end-to-end digital front door is more comprehensive.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage Healthcare Services Clients (AHSCs) in Q3 FY2026: \u003cstrong\u003e4,520\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Revenue per AHSC in Q3 FY2026: \u003cstrong\u003e$26,622\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eCostly and time-consuming. Building a platform that handles intake, outreach, and education across millions of visits requires significant R\u0026amp;D investment.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses as a percentage of revenue in Q3 FY2026: \u003cstrong\u003e24%\u003c\/strong\u003e (down from \u003cstrong\u003e25%\u003c\/strong\u003e in FY2022).\u003c\/li\u003e\n\u003cli\u003eSales and marketing expenses as a percentage of revenue in Q3 FY2026: \u003cstrong\u003e20%\u003c\/strong\u003e (down from \u003cstrong\u003e50%\u003c\/strong\u003e in FY2022).\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses as a percentage of revenue in Q3 FY2026: \u003cstrong\u003e15%\u003c\/strong\u003e (down from \u003cstrong\u003e32%\u003c\/strong\u003e in FY2022).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eGood. Their recognition on the 2025 Deloitte Technology Fast 500™ suggests strong product development execution.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhreesia was named to the \u003cstrong\u003e2025 Deloitte Technology Fast 500™\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDeloitte Technology Fast 500™ award eligibility requires a minimum revenue growth rate of \u003cstrong\u003e50%\u003c\/strong\u003e from 2021 to 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. While proprietary, the pace of AI\/SaaS development means a competitor could leapfrog them with a newer architecture.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY2026 Revenue Outlook: \u003cstrong\u003e$479 million\u003c\/strong\u003e to \u003cstrong\u003e$481 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2027 Revenue Projection: \u003cstrong\u003e$545 million\u003c\/strong\u003e to \u003cstrong\u003e$559 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Diversified, High-Margin Revenue Mix\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Stability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe diversified revenue structure provides inherent stability against fluctuations in any single market segment. The revenue mix for Q3 FY2026 was composed of:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Stream\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2026 Revenue (in thousands)\u003c\/td\u003e\n\u003ctd\u003ePercentage of Total Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription and related services\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55,480\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayment processing fees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27,422\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork solutions\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$37,431\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120,333\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company reported a Gross Margin of \u003cstrong\u003e61.35%\u003c\/strong\u003e for the quarter. Profitability metrics for the quarter include Net Income of \u003cstrong\u003e$4.3 million\u003c\/strong\u003e and Adjusted EBITDA of \u003cstrong\u003e$29.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Moderate\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eWhile many competitors operate in adjacent spaces, achieving this specific three-pronged revenue balance is less common.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSubscription and related services revenue grew \u003cstrong\u003e12%\u003c\/strong\u003e year-over-year in Q3 FY2026.\u003c\/li\u003e\n\u003cli\u003ePayment processing fees revenue grew \u003cstrong\u003e11%\u003c\/strong\u003e year-over-year in Q3 FY2026.\u003c\/li\u003e\n\u003cli\u003eNetwork solutions revenue increased \u003cstrong\u003e14%\u003c\/strong\u003e year-over-year in Q3 FY2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Moderate\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eReplicating the scale and integration across all three revenue vectors requires significant time and investment in distinct technological and sales capabilities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSubscription and related services revenue CAGR from FY2019 to FY2025 was \u003cstrong\u003e28%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePayment processing fees revenue CAGR from FY2019 to FY2025 was \u003cstrong\u003e18%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNetwork solutions revenue CAGR from FY2019 to FY2025 was \u003cstrong\u003e36%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Strong\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eManagement focus is evidenced by consistent growth across all segments and significant operating leverage improvements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage Healthcare Services Clients (AHSCs) totaled \u003cstrong\u003e4,520\u003c\/strong\u003e in Q3 FY2026, up \u003cstrong\u003e7%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eTotal revenue per AHSC was \u003cstrong\u003e$26,622\u003c\/strong\u003e in Q3 FY2026, up \u003cstrong\u003e6%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eSales and marketing expenses decreased from \u003cstrong\u003e50%\u003c\/strong\u003e of revenue in FY2022 to \u003cstrong\u003e20%\u003c\/strong\u003e in Q3 FY2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe current structure is advantageous, but the competitive landscape is dynamic, with potential for new models to emerge that favor concentration.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFY2026 Outlook (Updated)\u003c\/td\u003e\n\u003ctd\u003eFY2027 Outlook (Introduced)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$479 million\u003c\/strong\u003e to \u003cstrong\u003e$481 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$545 million\u003c\/strong\u003e to \u003cstrong\u003e$559 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$99 million\u003c\/strong\u003e to \u003cstrong\u003e$101 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$125 million\u003c\/strong\u003e to \u003cstrong\u003e$135 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe FY2027 revenue outlook represents a \u003cstrong\u003e14-16%\u003c\/strong\u003e increase over the fiscal 2026 outlook.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Proven Capability in Strategic M\u0026amp;A Integration\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eProven Capability in Strategic M\u0026amp;A Integration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Allows for rapid expansion into adjacent, high-value markets, as seen with the late 2025 AccessOne acquisition, which bolsters receivables financing. AccessOne manages a receivables portfolio of approximately \u003cstrong\u003e$450 million\u003c\/strong\u003e and generates a blended take rate that averages \u003cstrong\u003e4% to 12%\u003c\/strong\u003e on its managed portfolio.\u003c\/p\u003e\n\u003cp\u003eRarity: Moderate. Many tech companies struggle with post-merger integration; Phreesia successfully closed the \u003cstrong\u003e$160 million\u003c\/strong\u003e all-cash deal on November 12, 2025.\u003c\/p\u003e\n\u003cp\u003eImitability: Difficult. It requires capital access, deal-sourcing expertise, and operational alignment post-close. The acquisition was funded with cash reserves and a \u003cstrong\u003e$110 million\u003c\/strong\u003e secured bridge loan.\u003c\/p\u003e\n\u003cp\u003eOrganization: Needs Scrutiny. While the deal closed, the immediate strain on cash (using \u003cstrong\u003e$106.4 million\u003c\/strong\u003e in cash and cash equivalents as of October 31, 2025, alongside the bridge loan) shows a near-term risk in their organizational liquidity management.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary. Success depends on the execution of this specific integration; a future failed acquisition would erase this advantage.\u003c\/p\u003e\n\u003cp\u003ePhreesia's recent financial performance demonstrates operational leverage supporting M\u0026amp;A integration capability:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal revenue for the quarter ended October 31, 2025, was \u003cstrong\u003e$120.3 million\u003c\/strong\u003e, up \u003cstrong\u003e13%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA for the quarter reached \u003cstrong\u003e$29.1 million\u003c\/strong\u003e, representing an all-time high Adjusted EBITDA margin of \u003cstrong\u003e24%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet income for the quarter was \u003cstrong\u003e$4.3 million\u003c\/strong\u003e, marking the second consecutive quarter of positive net income.\u003c\/li\u003e\n\u003cli\u003eFree cash flow was \u003cstrong\u003e$8.8 million\u003c\/strong\u003e for the quarter.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe strategic outlook post-acquisition includes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2026 Outlook (Updated)\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2027 Outlook (Introduced)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$479 million\u003c\/strong\u003e to \u003cstrong\u003e$481 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$545 million\u003c\/strong\u003e to \u003cstrong\u003e$559 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessOne Revenue Contribution\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$7.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e6.5%\u003c\/strong\u003e of total revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$99 million\u003c\/strong\u003e to \u003cstrong\u003e$101 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$125 million\u003c\/strong\u003e to \u003cstrong\u003e$135 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Demonstrated Path to Profitability and Cash Flow\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial flexibility and investor confidence, moving from net loss to net income of \u003cstrong\u003e$4.3 million\u003c\/strong\u003e in Q3 FY2026 and positive Free Cash Flow of \u003cstrong\u003e$8.8 million\u003c\/strong\u003e in the same period.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. In the health-tech space, consistent profitability is still rare, especially after years of investment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. It requires disciplined cost control and operating leverage, which is a cultural trait, not just a process.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The focus on margin improvement is clearly working, with Adjusted EBITDA soaring to \u003cstrong\u003e$29.1 million\u003c\/strong\u003e in the quarter.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Once a company proves it can generate cash flow at scale, it changes how the market values it.\u003c\/p\u003e\n\u003cp\u003eThe transition to profitability is evidenced by key financial metrics from the fiscal third quarter ended October 31, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2026 Result\u003c\/td\u003e\n\u003ctd\u003ePrior Year Period Result\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNet Loss of \u003cstrong\u003e$14.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSignificant Turnaround\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e$19.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated\u003c\/td\u003e\n\u003ctd\u003eRecord-High Margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e$7.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Provided by Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e$9.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational scale and efficiency are further demonstrated by client metrics and revenue performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Revenue for the quarter was \u003cstrong\u003e$120.3 million\u003c\/strong\u003e, representing a \u003cstrong\u003e13%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eAverage number of healthcare services clients (AHSCs) reached \u003cstrong\u003e4,520\u003c\/strong\u003e, up \u003cstrong\u003e7%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eTotal revenue per AHSC was \u003cstrong\u003e$26,622\u003c\/strong\u003e, reflecting a \u003cstrong\u003e6%\u003c\/strong\u003e year-over-year growth.\u003c\/li\u003e\n\u003cli\u003eThe revenue mix for Q3 FY2026 consisted of \u003cstrong\u003e46%\u003c\/strong\u003e from subscription and related services, \u003cstrong\u003e23%\u003c\/strong\u003e from payment processing fees, and \u003cstrong\u003e31%\u003c\/strong\u003e from network solutions.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents stood at \u003cstrong\u003e$106.4 million\u003c\/strong\u003e as of October 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company's outlook reinforces the expectation of sustained financial improvement:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal Year Outlook\u003c\/td\u003e\n\u003ctd\u003eRevenue Range\u003c\/td\u003e\n\u003ctd\u003eAdjusted EBITDA Range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2026 (Updated)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$479 million\u003c\/strong\u003e to \u003cstrong\u003e$481 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$99 million\u003c\/strong\u003e to \u003cstrong\u003e$101 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2027 (Introduced)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$545 million\u003c\/strong\u003e to \u003cstrong\u003e$559 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$125 million\u003c\/strong\u003e to \u003cstrong\u003e$135 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Deep Data Assets from High Patient Volume\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Fuels network solutions and future AI\/ML product development; they processed over \u003cstrong\u003e$4 billion\u003c\/strong\u003e in patient payments in the last twelve months.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. The volume of patient visits - estimated at approximately \u003cstrong\u003e170 million\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e, representing \u003cstrong\u003e1 in 7\u003c\/strong\u003e visits across the U.S. - creates a data moat.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very Difficult. Competitors cannot easily replicate the scale of patient interactions or the established compliance framework surrounding that data volume.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. Monetization is evident through the Network Solutions stream, which contributed significantly to recent revenue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Data scale, when legally and ethically managed, is a powerful, hard-to-replicate asset.\u003c\/p\u003e\n\u003cp\u003eKey Metrics Illustrating Data Scale and Monetization (Q3 FY2026 Data):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eContext\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Visits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e170 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximate for 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Payments Processed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast Twelve Months (LTM)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Healthcare Services Clients (AHSCs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,520\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork Solutions Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$37,431\u003c\/strong\u003e thousand\u003c\/td\u003e\n\u003ctd\u003eThree Months Ended October 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork Solutions Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRevenue Mix for Q3 FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther financial details supporting the scale and revenue generation include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNetwork solutions revenue for the nine months ended October 31, 2025, totaled \u003cstrong\u003e$104,248\u003c\/strong\u003e thousand.\u003c\/li\u003e\n\u003cli\u003eTotal revenue for Q3 FY2026 was \u003cstrong\u003e$120.3 million\u003c\/strong\u003e, up \u003cstrong\u003e13%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eTotal revenue per AHSC in Q3 FY2026 was \u003cstrong\u003e$26,622\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company maintained a positive net income of \u003cstrong\u003e$4.3 million\u003c\/strong\u003e in Q3 FY2026, marking its second consecutive quarter of profitability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: High Customer Retention and Expansion (Revenue per AHSC Growth)\n\u003c\/h2\u003e\n\u003cp\u003eThis analysis focuses on the metric of Total Revenue per Average Healthcare Services Client (AHSC) growth as an indicator of customer retention and expansion success.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eIndicates high customer satisfaction and successful cross-selling, as Total revenue per AHSC grew \u003cstrong\u003e6%\u003c\/strong\u003e year-over-year in Q3 FY2026, reaching \u003cstrong\u003e$26,622\u003c\/strong\u003e. This metric demonstrates Phreesia's ability to both retain clients and expand revenue within its existing client base. The total revenue for Q3 FY2026 was \u003cstrong\u003e$120.3 million\u003c\/strong\u003e, a \u003cstrong\u003e13%\u003c\/strong\u003e increase year-over-year.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 FY2026 Value\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue per AHSC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26,622\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage AHSCs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,520\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. While many SaaS companies achieve good retention, consistently growing revenue within the existing base, as evidenced by the \u003cstrong\u003e6%\u003c\/strong\u003e Total Revenue per AHSC growth, is a sign of superior product-market fit. This metric returned to levels last seen in the third quarter of fiscal 2022.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult. Requires a product roadmap that continuously adds value beyond the initial sale, evidenced by the diversified revenue mix and strategic acquisitions like AccessOne, which closed in Q3 FY2026 for approximately \u003cstrong\u003e$160 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eStrong. This metric is a direct result of effective account management and product development alignment, reflected in the company's improved profitability and cash flow generation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Income in Q3 FY2026: \u003cstrong\u003e$4.3 million\u003c\/strong\u003e (compared to a net loss of \u003cstrong\u003e$14.4 million\u003c\/strong\u003e prior year).\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA in Q3 FY2026: \u003cstrong\u003e$29.1 million\u003c\/strong\u003e (nearly tripling year-over-year, up \u003cstrong\u003e198%\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eNet cash provided by operating activities in Q3 FY2026: \u003cstrong\u003e$15.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFree cash flow in Q3 FY2026: \u003cstrong\u003e$8.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. High retention locks in future revenue streams, making the business inherently more valuable. The company projects continued growth, with FY2027 revenue outlook in the range of \u003cstrong\u003e$545 million to $559 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Brand Recognition in HealthTech Leadership\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Enhances credibility for large enterprise sales and attracts top talent; named to TIME’s 2025 List of the World’s Top HealthTech Companies. Facilitating approximately \u003cstrong\u003e170 million\u003c\/strong\u003e patient visits in \u003cstrong\u003e2024\u003c\/strong\u003e, representing \u003cstrong\u003e1 in 7\u003c\/strong\u003e visits across the U.S..\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Q3 FY2026)\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Healthcare Services Clients (AHSCs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,520\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue per AHSC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26,622\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTurnaround from net loss of \u003cstrong\u003e$14.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+198%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Addressable Market (TAM)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$24 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many firms get awards, being recognized by top-tier publications signals market validation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNamed to \u003cstrong\u003eTIME’s 2025 List of the World’s Top HealthTech Companies\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRecognized on the \u003cstrong\u003e2025 Deloitte Technology Fast 500™\u003c\/strong\u003e list.\u003c\/li\u003e\n\u003cli\u003eIncluded as one of The Software Report’s \u003cstrong\u003eTop 50 Software Companies of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Brand equity is built over time through consistent performance and positive press.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. Management effectively communicates successes to the market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While helpful now, brand value can erode quickly with a major service failure or scandal.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePhreesia, Inc. (PHR) - VRIO Analysis: Scalable, Remote-First Operating Model\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for lower overhead and access to a wider talent pool, as evidenced by being an all-remote company with \u003cstrong\u003e2,082\u003c\/strong\u003e employees as of January 31, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Post-2020, many adopted remote work, but Phreesia has optimized it for scale.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy. Other companies can adopt a remote structure, but the cultural shift takes time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. This structure supports their growth trajectory, projecting FY2027 revenue up to \u003cstrong\u003e$559 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s an efficiency lever, but not a unique differentiator in the long run.\u003c\/p\u003e\n\u003cp\u003eThe operational model supports significant financial scaling, as demonstrated by recent performance and forward guidance:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 FY2026 Actual\u003c\/th\u003e\n\u003cth\u003eFY2026 Outlook Range\u003c\/th\u003e\n\u003cth\u003eFY2027 Projection\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$479 million\u003c\/strong\u003e - \u003cstrong\u003e$481 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$545 million\u003c\/strong\u003e - \u003cstrong\u003e$559 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$99 million\u003c\/strong\u003e - \u003cstrong\u003e$101 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$125 million\u003c\/strong\u003e - \u003cstrong\u003e$135 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Healthcare Services Clients (AHSCs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,520\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e4,515\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey operational statistics supporting the model include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal revenue per AHSC in Q3 FY2026 grew by \u003cstrong\u003e6%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$26,622\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAHSCs increased by \u003cstrong\u003e7%\u003c\/strong\u003e year-over-year in Q3 FY2026 to \u003cstrong\u003e4,520\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTrailing Twelve Month (TTM) Revenue as of July 31, 2025, was \u003cstrong\u003e$450 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross Margin is reported at \u003cstrong\u003e68.02%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe integration of the AccessOne acquisition, which is a key component of the FY2027 projection, involved specific financing activities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAccessOne Acquisition Total Consideration: \u003cstrong\u003e$160 million\u003c\/strong\u003e in cash.\u003c\/li\u003e\n\u003cli\u003eFinancing Structure: Funded through cash from the balance sheet and a new secured term loan of \u003cstrong\u003e$110 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAccessOne Managed Receivables Portfolio: Approximately \u003cstrong\u003e$450 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected AccessOne Contribution to FY2027 Revenue: Approximately \u003cstrong\u003e6.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePro-forma Cash Flow Statement Incorporation Data (AccessOne Acquisition Funding):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe financing for the \u003cstrong\u003e$160 million\u003c\/strong\u003e AccessOne acquisition impacts the Cash Flow from Financing Activities section:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash Flow from Financing Activities - Proceeds from New Secured Term Loan: \u003cstrong\u003e+$110,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Flow from Financing Activities - Acquisition Consideration Paid: \u003cstrong\u003e-$160,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Cash Flow Impact from Financing (Loan \u0026amp; Payment): \u003cstrong\u003e-$50,000,000\u003c\/strong\u003e (before accounting for cash used from balance sheet\/acquired cash).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516230885525,"sku":"phr-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/phr-vrio-analysis.png?v=1740205965","url":"https:\/\/dcf-model.com\/pt\/products\/phr-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}